H-D-Ser-OH
(Synonyms: D-丝氨酸; (R)-Serine) 目录号 : GA11306
An NMDA co-agonist
Cas No.:312-84-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
(R)-Serine, an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics, is a potent co-agonist at the NMDA glutamate receptor. (R)-Serine has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration[1][2].
(R)-Serine is synthesized from L-Ser by serine racemase (SR) and degraded by D-amino acid oxidase (DAAO) and SR. Distribution of D-Ser and NMDAR as determined by chemical measurement and immunohistochemistry supports D-Ser as an endogenous coagonist acting on the glycine modulatory site of the NR1 subunits of the NMDAR[3].
(R)-Serine (10 g/L; p.o.; throughout 8 weeks) regulates HFD induced weight gain[4].
References:
[1]. Andrea R. Durrant, et al. D-Serine in Neuropsychiatric Disorders: New Advances.
[2]. MacKay MB, et al. D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression Front Psychiatry. 2019 Feb 6;10:25.
[3]. Dai X, et al. D-Serine made by serine racemase in Drosophila intestine plays a physiological role in sleep. Nat Commun. 2019 May 7;10(1):1986.
[4]. Suwandhi L, et al. Chronic d-serine supplementation impairs insulin secretion. Mol Metab. 2018 Oct;16:191-202.
| Cas No. | 312-84-5 | SDF | |
| 别名 | D-丝氨酸; (R)-Serine | ||
| 化学名 | (2R)-2-amino-3-hydroxypropanoic acid | ||
| Canonical SMILES | C(C(C(=O)O)N)O | ||
| 分子式 | C3H7NO3 | 分子量 | 105.09 |
| 溶解度 | PBS (pH 7.2): 5mg/mL | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 9.5157 mL | 47.5783 mL | 95.1565 mL |
| 5 mM | 1.9031 mL | 9.5157 mL | 19.0313 mL |
| 10 mM | 0.9516 mL | 4.7578 mL | 9.5157 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。